ARCHIVES

Phase II Elotuzumab Study Demonstrates 33 Months PFS

This article is from The Cancer Letter archive.

Vol. 36 No. 7 | July 26, 2013

Download PDF Visit The Full Archive

Related Articles

The March: Research Task Force Calls For $10 Billion NCI Budget In 5 Years

October 2, 1998

FDA Invites Ad Hoc Consumer Reps To ODAC Meetings

February 17, 1995

NCI Forms Lung Cancer Program for Research On Early Detection, Treatment.

June 23, 2006

Other Institutes Fare Well With ’77 Appropriations

August 20, 1976

Two More Treatment Programs Moved To DCT; Rauscher Ponders Fate of Cooperative Groups

April 18, 1975

Phase II Trial of BIND-014 Shows Anti-Tumor Activity in Q3W Arm

November 28, 2014